In a historic milestone for European public health, the World Health Organization (WHO) has officially certified Denmark for the elimination of mother-to-child transmission (EMTCT) of both HIV and syphilis. This certification distinguishes Denmark as the first country within the European Union to achieve this dual validation, signaling a triumphant culmination of decades of integrated healthcare strategies, robust prenatal screening, and a steadfast commitment to universal health coverage. The recognition confirms that Denmark has established a healthcare infrastructure capable of ensuring that virtually every child in the kingdom is born free of these two life-altering infections.
The WHO Director-General, Dr. Tedros Adhanom Ghebreyesus, lauded the achievement as a testament to the power of political will and sustained domestic investment. According to Dr. Tedros, the elimination of mother-to-child transmission of HIV and syphilis represents a major public health victory, demonstrating that when countries prioritize primary care and integrate maternal and child health services, they can effectively shield the most vulnerable—pregnant women and their newborns—from the burdens of these diseases. The Director-General emphasized that Denmark’s success serves as a blueprint for other high-income and developing nations alike, proving that consistent application of evidence-based interventions yields definitive results.
The Rigorous Path to WHO Certification
The journey toward validation was characterized by a meticulous multi-stage assessment process. The certification follows an exhaustive review conducted by the WHO Regional Validation Committee in June 2025, followed by a final appraisal by the Global Validation Advisory Committee (GVAC) in August 2025. These committees evaluated Denmark’s public health data from the period of 2021 to 2024, verifying that the nation consistently met or exceeded the stringent international targets required for EMTCT status.
To receive WHO certification, a country must prove not only low transmission rates but also high levels of service coverage. Specifically, the benchmarks require that at least 95% of all pregnant women receive prenatal testing for HIV and syphilis, and that those who test positive receive immediate and effective treatment. Furthermore, the rate of new infant infections must be maintained below 50 per 100,000 live births over a sustained period. Denmark’s ability to provide granular, high-quality data over several years was a decisive factor in the GVAC’s decision, showcasing the reliability of the Danish national health registries and laboratory networks.
Dr. Hans Henri P. Kluge, the WHO Regional Director for Europe, highlighted the significance of Denmark’s leadership within the region. He noted that as the first EU member state to reach this milestone, Denmark has set a high standard for its neighbors. Dr. Kluge pointed out that the achievement is rooted in the country’s "test and treat" philosophy, where the healthcare system ensures that the vast majority of pregnant women are screened early and managed with the highest standards of clinical care. He also emphasized that Denmark’s respect for human rights and the elimination of stigma surrounding HIV and syphilis were essential components in encouraging women to seek and stay in care.
Quantifying Success: Benchmarks and Statistical Milestones
Denmark’s achievement is supported by a wealth of clinical data that illustrates the effectiveness of its public health interventions. Currently, approximately 5,950 individuals are living with HIV in Denmark, a relatively low figure that reflects the country’s successful long-term management of the epidemic. Among the pregnant population, the prevalence of HIV is exceptionally low, affecting fewer than 0.1% of expectant mothers. Through routine, opt-out prenatal testing and the immediate administration of antiretroviral therapy (ART) to those in need, Denmark has effectively reduced mother-to-child transmission rates to zero.
The data regarding syphilis is equally compelling. While many parts of the world have seen a resurgence in syphilis cases over the last decade, Denmark has managed to keep congenital syphilis—where the infection is passed from mother to baby—virtually non-existent. In 2024, the country reported 626 total cases of syphilis. A demographic breakdown of these cases shows a significant gender disparity, with 524 cases occurring in men and 102 in women. By identifying and treating these cases among women of childbearing age through systematic prenatal screening, the Danish health system has successfully prevented the transmission of the bacteria to newborns, avoiding the severe complications associated with congenital syphilis, such as stillbirth or neonatal death.
Regarding Hepatitis B, which is the third component of the WHO’s "triple elimination" goal, Denmark maintains a low prevalence of chronic infection, estimated at between 0.2% and 0.3%. These cases are primarily identified among migrant populations from regions where the virus is endemic. The country’s robust screening programs and infant vaccination protocols have put it on a clear trajectory toward validating the elimination of Hepatitis B in the near future.
The Danish Model: Universal Access and Integrated Care
The foundation of Denmark’s success lies in its universal healthcare system, which is funded through taxation and provides equal access to medical services for all residents, regardless of socioeconomic status or legal residency. Sophie Løhde, Denmark’s Minister for the Interior and Health, expressed immense pride in the validation, attributing it to the collective efforts of midwives, nurses, physicians, and public health researchers.
"This validation by WHO is a proud moment for Denmark," Minister Løhde stated. "Our universal health system—built on equal access for all—has been the foundation of this achievement. Being the first country in the European Union to reach this milestone is both an honor and a responsibility." She further noted that the Danish approach integrates screening into routine antenatal visits, making it a standard part of the pregnancy journey rather than a separate, stigmatized procedure. This integration ensures high uptake and allows for early intervention, which is critical for preventing transmission.
Beyond clinical care, Denmark’s success is bolstered by its sophisticated laboratory capacity and data-driven policy-making. The country’s ability to track every case of HIV and syphilis from diagnosis through treatment allows health authorities to identify gaps in service delivery and address them in real-time. This level of surveillance ensures that no pregnant woman falls through the cracks of the healthcare system.
Global Context and the Path to Triple Elimination
Denmark joins an elite group of 22 other countries and territories that have been validated by the WHO for the elimination of mother-to-child transmission of HIV, syphilis, or Hepatitis B. This diverse list includes nations such as Cuba (the first to be validated in 2015), Thailand, Malaysia, Sri Lanka, Oman, and several Caribbean nations like Anguilla, Antigua and Barbuda, and Bermuda. In recent years, African nations such as Botswana and Namibia have also made significant strides, being certified on the "path to elimination," showcasing that the goal is achievable across different economic contexts.
However, Denmark’s certification is particularly noteworthy as it signals a shift in the European landscape. While many Western European nations have low transmission rates, the formal WHO validation process requires a level of documented evidence and systemic rigor that many countries have not yet formalized. Denmark’s willingness to undergo this rigorous assessment sets a precedent for other EU member states to seek official validation, potentially leading to a region-wide push for elimination.
The next frontier for Denmark is the achievement of "triple elimination," which includes the elimination of mother-to-child transmission of the Hepatitis B virus (HBV). The WHO is currently collaborating with Danish health authorities to advance this process. Achieving triple elimination would represent the highest level of maternal and child health protection, ensuring a generation born entirely free of three of the most significant blood-borne and sexually transmitted infections.
Implications for Public Health and Policy
The implications of Denmark’s certification extend far beyond its borders. It serves as a powerful motivator for the global health community, proving that the elimination of vertical transmission is a realistic and sustainable goal. For policymakers, the Danish experience underscores the necessity of rights-based policies. By ensuring that healthcare is accessible and that the rights of women—including their right to privacy and non-discriminatory treatment—are protected, countries can foster an environment where public health goals are met with high community cooperation.
Furthermore, Denmark’s success highlights the importance of maintaining "pathway" programs for migrant and vulnerable populations. As the data on Hepatitis B suggests, many new cases of these infections in low-prevalence countries occur within mobile populations. Denmark’s ability to reach these groups and provide them with the same high standard of prenatal care as the general population has been vital to achieving its zero-transmission targets.
As Denmark continues to refine its strategies and moves toward the triple elimination of HIV, syphilis, and Hepatitis B, it provides a functional model of how high-quality services, strong data systems, and a commitment to equity can transform public health. The WHO and the Danish government have both expressed their hope that this milestone will inspire other nations to strengthen their own EMTCT programs, moving the world closer to a future where mother-to-child transmission of these diseases is a thing of the past.